Rnai agent for inhibiting hbv expression and use thereof
AssigneeOliX Pharmaceuticals, Inc.
InventorsSun Woo HONG, Pooja DUA
Life of this patent
Estimating the term…
Abstract
The present application relates to an RNA interference (RNAi) agent for inhibiting the expression of hepatitis B virus and uses thereof, and to an RNAi agent that inhibits the expression of hepatitis B virus and a pharmaceutical composition including the RNAi agent for amelioration or treatment of diseases caused by hepatitis B virus infection.
Claims14
An RNA interference (RNAi) agent for inhibiting the expression of hepatitis B virus(HBV), comprising a sense strand and an antisense strand, wherein
- the antisense strand has a length of 19 nt to 23 nt,
- the sense strand has a length of 15 nt to 17 nt, forms a complementary bond with the antisense strand, comprises a sequence selected from the group consisting of SEQ ID NOs:
- 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 37, 39, 41, 43, 45, 47, 49, 51, and 53, and comprises a polyvalent galactose or N-acetyl-galactosamine derivative, and
- the 5′ end of the antisense strand and the 3′ end of the sense strand form a blunt end.
An RNA interference (RNAi) agent for inhibiting the expression of hepatitis B virus, comprising a sense strand and an antisense strand, wherein
- the antisense strand has a length of 19 nt to 23 nt,
- the sense strand has a length of 15 nt to 17 nt, forms a complementary bond with the antisense strand, comprises a sequence selected from the group consisting of SEQ ID NOs:
- 21, 23, 25, 27, 29, 31, 33, 35, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, and 75, and comprises a polyvalent galactose or N-acetyl-galactosamine derivative, and
- the 5′ end of the antisense strand and the 3′ end of the sense strand form a blunt end.
Dependencies are inferred from the claim text.